about
Myasthenia gravis and thymic neoplasms: A brief reviewFuture perspectives in target-specific immunotherapies of myasthenia gravisIndividualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.Early fast-acting treatment strategy against generalized myasthenia gravis.Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Targeting therapy to the neuromuscular junction: proof of concept.Myasthenia gravis: a review of available treatment approaches.Treatment of myasthenia gravis based on its immunopathogenesisAn up-date on health-related quality of life in myasthenia gravis -results from population based cohortsSubcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq StudyPreoperative high-dose steroid has long-term beneficial effects for myasthenia gravis.Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients.Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.Diagnostic use of autoantibodies in myasthenia gravis.Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease.The thymus in myasthenia gravis: Site of "innate autoimmunity"?Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.The emerging role of tacrolimus in myasthenia gravis.Overcoming challenges in the diagnosis and treatment of myasthenia gravis.Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry.Thymoma in myasthenia gravis: from diagnosis to treatment.Successful Lung Transplantation in a Patient with Myasthenia Gravis.Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.Health-related quality-of-life and treatment targets in myasthenia gravis.Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.Factors affecting outcome in myasthenia gravis.Insights in the autoimmunity of myasthenia gravis.Treatment of MuSK-Associated Myasthenia Gravis.Antigen-specific apheresis of autoantibodies in myasthenia gravis.Management challenges in muscle-specific tyrosine kinase myasthenia gravis.Prompt Response to Prednisone Predicts Benign Course in MuSK-MG.Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.Recurrent Opportunistic Infections in a Thymectomised Patient with Myasthenia Gravis and Good's Syndrome
P2860
Q26775077-8B760F82-7CA3-4B93-9BC7-327598A148ACQ26776225-39CF7002-C991-4C36-9CC1-8F2C9B8B3D56Q30373969-5FC2E4E7-1B3C-4C34-B5E7-820B7EC9BC7BQ33834012-B3DC3183-312C-4729-8671-339E776BAC65Q33916520-5AD305C8-B1EF-47EB-A5F6-136AEDA5BB28Q34257903-C7CF8E81-C9D8-4EB5-8CA6-A564CDF36E0FQ34974981-019E0F81-0BE0-437C-AE92-3EF7BB28351EQ35293574-7271CA8C-31BE-4FDB-AE1B-C15E36B4190FQ35675970-1B44E6BC-0097-498B-A9D0-19EB82E32501Q35908237-7D9E93FA-BD5C-4586-902A-76C698360F73Q36094658-F10DB2B0-00C5-454C-8763-39B426863502Q36484383-749EC3DC-46C7-4C68-8FE7-B7ABF79889F3Q36614763-68C09024-54B2-4F6C-B1E5-6AEC27D45804Q37057779-F2CD7337-4060-4813-A746-AC408A5D1EB7Q37427333-6BDA1D3B-7ADD-4443-8BF4-7C12C000E3B4Q37681359-14D6D8D4-0620-4691-9816-D1D718B7597EQ37727987-83F678F7-06E3-4006-A31B-6489CD9E1130Q37727994-011C4DDC-A8DE-4EF1-A3EC-55A8767782F8Q37730681-EDF1193B-6898-4BB8-9712-BEFED964AD92Q37933171-FBDB7645-FFA9-4AD1-9A96-D10A457D176BQ37967185-EA83BAA5-9306-4BA4-8157-5701A8719134Q38068530-3082A286-BCE2-4BBC-B495-F4E8841CC416Q38068534-66200600-EDDA-4C42-9920-A31F8E9C9DD8Q38154934-FA561B93-BFF1-4FE3-A811-E0E13E9E9D4EQ38448460-F78D0A88-7A4A-42C6-AA6B-CFB42CA3C416Q38671442-C6ED6B4B-6547-4F7C-9897-B27EDD9FA123Q41109601-ED52983A-027D-4FFA-87AB-860AF10EEB28Q42150425-F684E9B5-CED9-4959-8189-217584AAB3B4Q47122292-69504A8C-B937-4C8F-BF18-CA231AD9F0EDQ47570833-A162BC60-FFF4-435C-9C63-05B69C13E7F8Q48085548-0013C205-53FE-47C5-8238-EA2F60906DE3Q49629485-DE783306-175F-49C2-92F0-7B75E3C86B64Q51725426-5CE8EDAC-2B7B-4450-A77D-AE73CFE20FEBQ51853050-AA89EA9B-A9D6-461C-AB9A-C7555BCE28E9Q54379059-31640C94-C432-4773-85A7-113CA6117EA3Q54461110-9C0D72AC-CD4F-48B5-8B52-1A1E3BBC4A23Q54464610-1A6D6206-FC24-4CFA-94AB-66AA4B867FB5Q54990030-93FA1EDB-DA2C-4CF8-8692-981FC61D28AFQ55267717-D80D3936-E923-4CC4-A1B1-440D176C20D4Q57824154-06920C51-D6FB-4883-BF06-39A589296787
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunosuppressive therapies in myasthenia gravis.
@en
Immunosuppressive therapies in myasthenia gravis.
@nl
type
label
Immunosuppressive therapies in myasthenia gravis.
@en
Immunosuppressive therapies in myasthenia gravis.
@nl
prefLabel
Immunosuppressive therapies in myasthenia gravis.
@en
Immunosuppressive therapies in myasthenia gravis.
@nl
P2860
P1433
P1476
Immunosuppressive therapies in myasthenia gravis.
@en
P2093
Amelia Evoli
Donald B Sanders
P2860
P304
P356
10.3109/08916930903518107
P577
2010-08-01T00:00:00Z